NEW YORK, Sept. 17 — EuroProteome announced today that it has secured €9.5 million in a financing round. The Hennigsdorf, Germany-based company, which calls itself a "human cancer proteomiucs company," is developing clinical tools for early diagnostics, prognostics, and patient-specific therapeutics and immune therapeutics for the treatment of epithelial cancers. The round was led by German VC firms Earlybird Venture Capital and Heidelberg Innovation. Nextech Venture and Aventic Partners, both of Zurich, also contributed.